Anadys Pharmaceuticals Inc.

Steve Worland, Ph.D. was appointed President and Chief Executive Officer and a member of the Board of Directors on August 24, 2007. Dr. Worland joined Anadys as Chief Scientific Officer in 2001. In October 2004 he was promoted to Executive Vice President, Head of Research and Development, in December 2005. Dr. Worland was named Executive Vice President, Pharmaceuticals, and in June 2006 he was promoted to President, Pharmaceuticals. From 1999 to 2001 he was Vice President, Head of Antiviral Research, at Agouron Pharmaceuticals, a Pfizer Company. Dr. Worland was at Agouron from 1988 through the acquisition of Agouron by Warner-Lambert in 1999,where he held various positions and responsibilities that culminated with him assuming global responsibility for anti-infective strategy as Vice President for Warner-Lambert. At Agouron, Warner-Lambert and Pfizer, Dr. Worland led teams responsible for discovery and clinical development in the areas of HIV, HCV and Rhinovirus. Dr. Worland was a National Institutes of Health Postdoctoral Fellow in Molecular Biology at Harvard University from 1985 to 1988. He received his B.S. in Biological Chemistry from the University of Michigan and his Ph.D. in Chemistry from the University of California, Berkeley.

James L. Freddo, M.D., joined Anadys in July 2006 as Chief Medical Officer and was named Senior Vice President, Drug Development and Chief Medical Officer in July 2008. Prior to joining Anadys, Dr. Freddo was Vice President, Clinical Site Head and Development Site Head for Pfizer Global Research and Development, La Jolla. Previously at Pfizer, he was Executive Director, Site Therapeutic Area Leader, Clinical Development, Oncology. While at Pfizer, Dr. Freddo led the team responsible for the registration of Sutent (sunitinib malate), a drug approved by the U.S. Food and Drug Administration in January 2006 for treating advanced kidney cancer and gastrointestinal stromal tumors. Prior to Pfizer, Dr. Freddo held a variety of senior management positions at Wyeth-Ayerst Research from 1996 to 2002, including Senior Director, Oncology, Senior Director, Infectious Diseases and Senior Director, Transplantation Immunology. Dr. Freddo currently serves as a member of the Board of Directors for InfuSystem Holdings, Inc. He holds a B.S degree in Medical Technology from the State University of New York at Stony Brook, Stony Brook, NY, and a M.D. degree from the University of North Carolina, Chapel Hill, NC, where he also completed his fellowship training.

James T. Glover joined Anadys in September 2006 as Senior Vice President, Operations and Chief Financial Officer. Mr. Glover joined Anadys from Beckman Coulter, Inc., a $2.4 billion global clinical diagnostics and biomedical research company, where he served as Senior Vice President and Chief Financial Officer since 2003. During his 17-year tenure at Beckman Coulter, he held a variety of significant management positions including: Vice President, Controller and Chief Accounting Officer (2003); Vice President and Treasurer (1999 to 2003); Vice President and Controller (1993-1999); Vice President-Strategic Planning & Program Management, Diagnostic Division (1993); and Vice President-Controller/Divisional CFO (1989-1993). Prior to that, Jim worked for six years with several divisions of SmithKline Beckman, Inc., including Allergan Pharmaceuticals. Mr. Glover currently serves as a member of the Board of Directors of Varian, Inc. Mr. Glover, a certified public accountant, holds a Master of Business Administration from Pepperdine University and a B.S. in Accounting from California State Polytechnic University.

Elizabeth E. Reed, J.D., was promoted to Vice President, Legal Affairs and Corporate Secretary in December 2006. Previously, she had served as Senior Director, Legal Affairs and Corporate Secretary since December 2002. From January 2002 through December 2002 she was Director, Legal Affairs and Corporate Secretary and from October 2001 through January 2002 she was Director, Legal Affairs. Prior to joining Anadys, Ms. Reed was associated with the law firm of Cooley Godward LLP from 1998 to 2001. Prior to Cooley Godward, Ms. Reed was associated with the law firm of Brobeck, Phleger & Harrison LLP. Ms. Reed is a member of the State Bar of California and received her B.S. in Business Administration with an emphasis in finance from the Haas School of Business at the University of California, Berkeley and holds a J.D., cum laude, from Harvard Law School.

Mary Glanville has been passionate about human capital in the life sciences industry since 1993. She is currently the Vice President, Human Capital at Anadys Pharmaceuticals where she has served for the past 7 years. Prior positions include: Director of Human Resources at Inflazyme Inc and Director of Human Resources at Inex Pharmaceuticals. Prior to joining the life sciences industry, she held personnel and human resources positions at HBC Inc., and was a Systems Engineer for EDS of Canada. Mary studied psychology at the University of Toronto and holds a B.Sc. in Computer Information System Management from the DeVry Institute of Technology. Mary has a Human Resources Management Certificate from the British Columbia Institute of Technology and has received a Certified Human Resources Professional designation from the Canadian Human Resources Management Association. Mary is on the board of SDSHRM as well as the BEDC.

Stelios Papadopoulos, Ph.D. is a co-founder of Anadys and has served as a member of our board of directors since May 2000. His career in biotech spans more than two decades. In August 2006 he resigned as Vice Chairman of Cowen & Co., LLC where he had been an investment banker focused on the biotechnology and pharmaceutical sectors since 2000. Dr. Papadopoulos was an investment banker at PaineWebber Incorporated from 1987 to 2000, most recently serving as Chairman of Paine Webber Development Corp., a PaineWebber subsidiary focusing on biotechnology. Prior to joining PaineWebber in 1987 he was a Vice President in the Equity Research Department of Drexel Burnham Lambert covering the biotechnology industry and a biotechnology analyst at Donaldson, Lufkin & Jenrette. Before coming to Wall Street, Dr. Papadopoulos was on the faculty of the Department of Cell Biology at New York University Medical Center. He continues his affiliation with New York University Medical Center as an Adjunct Associate Professor of Cell Biology. Dr. Papadopoulos holds a Ph.D. in biophysics and an M.B.A. in finance, both from New York University. He is co-founder and Chairman of the Board of Exelixis, Inc., co-founder and member of the Board of Cellzome Inc., as well as a member of the Board of Directors of Biogen Idec and BG Medicine, Inc. In the not-for-profit sector, he is co-founder and Chairman of Fondation Santé and a member of the Board of Visitors of Duke University Medical Center.

Mr. White is Chief of Staff and Chief Administrative Officer of Cowen and Company. Previously, Mr. White was a member of SG Capital Partners, the Merchant Banking Division of Cowen, which he joined in 2003. Prior to joining the Merchant Banking Division, Mr. White was a member of the Equity Capital Markets Group of Cowen where he covered the technology and consumer sectors. Prior to this, Mr. White worked at Salomon Smith Barney in the Equity Capital Markets Group. In addition, Mr. White has seven years experience as a practicing securities and M&A lawyer at Brown Rudnick Freed & Gesmer and Lord Day & Lord, Barrett Smith. Mr. White received his B.A. from Amherst College and his J.D. from the University of Michigan Law School.

Mary Yaroshevsky-Glanville was promoted to Vice President, Human Capital in December 2005. She served as Anadys' Senior Director, Human Capital since August 2002 and Director of Human Capital from April 2001 to August 2002. From 2000 to 2001, Ms. Yaroshevsky- Glanville served as Director of Human Resources at Inflazyme Inc. Previously, Ms. Yaroshevsky-Glanville served as Director of Human Resources at Inex Pharmaceuticals Corp. from 1995 to 2000 and as Manager, Human Resources and Office Administration from 1994 through 1995. Prior to joining Inex, she held personnel and human resources positions at HBC, Inc. Ms. Yaroshevsky-Glanville has a Human Resources Management Certificate from the British Columbia Institute of Technology, has received a Certified Human Resources Professional designation from the Human Resources Management Association, and holds a B.Sc. in Computer Information System Management from the DeVry Institute of Technology.

Douglas E. Williams, Ph.D., age 51, has served as one of our directors and Chief Executive Officer since January 2009. Previously, Dr. Williams served as our President and Chief Scientific Officer from July 2007 to January 2009 and as our Executive Vice President, Research and Development and Chief Scientific Officer from November 2004 to July 2007. From September 2003 to August 2004, Dr. Williams served as Chief Scientific Officer and Executive Vice President, Research and Development of Seattle Genetics, Inc., a biotechnology company. From November 2002 to August 2003, he was Head of Health and Strategic Development of Genesis Research & Development Corporation, LTD, a New Zealand biotechnology company. From July 2002 to October 2002, Dr. Williams served as Senior Vice President and Washington Site Leader of Amgen, Inc., a biotechnology company. From October 1999 to July 2002, he served as Executive Vice President and Chief Technology Officer at Immunex Corporation, a biotechnology company that was acquired by Amgen in 2002, and served as Senior Vice President of Discovery Research at Immunex from October 1994 to October 1999. Dr. Williams serves as a director of Anadys Pharmaceuticals, Inc., Array BioPharma Inc. and Aerovance, Inc. Dr. Williams also serves on the scientific advisory board of Symphony Capital. Dr. Williams received a B.S. (magna cum laude) in Biological Sciences from the University of Massachusetts, Lowell and a Ph.D. in Physiology from the State University of New York at Buffalo, Roswell Park Cancer Institute Division.

Kleanthis G. Xanthopoulos, Ph.D. is one of our co-founders and has served as our President and Chief Executive Officer and as a Director since May 2000. From 1997 to 2000 he held a variety of positions at Aurora Biosciences Corporation, including Vice President, Genomics & Molecular Biology. Dr. Xanthopoulos was a Section Head of the National Human Genome Research Institute at The National Institutes of Health. Dr. Xanthopoulos was a Postdoctoral Research Fellow at the Rockefeller University from 1987 to 1990 and an Associate Professor of Molecular Biology at the Karolinska Nobel Medical Institute, Sweden from 1991 to 1995. Dr. Xanthopoulos is also a member of the board of directors of Odyssey Thera, Inc. and BIOCOM, Southern California s life science industry association. An Onassis Scholar, Dr. Xanthopoulos received his B.Sc. in Biology with honors from Aristotle University of Thessaloniki, Greece, and received both his M.Sc. in Microbiology and Ph.D. in Molecular Biology from the University of Stockholm, Sweden.

Lawrence C. Fritz joined Anadys as President and Chief Executive Officer and a member of the Board of Directors on November 20, 2006. Previously, he founded and developed several successful biotechnology companies. He founded Conforma Therapeutics and served as its President and CEO from inception in 1999 through its acquisition by Biogen Idec in 2006. Conforma pioneered a new approach to cancer therapy, developing drugs that induce tumor cells to degrade their deregulated signaling proteins. Dr. Fritz is also a founder and Director of Cabrellis Pharmaceuticals, a specialty pharma cancer company spun-out from Conforma in conjunction with Biogen Idec's acquisition. Prior to Conforma, Dr. Fritz co-founded both Athena Neurosciences, now wholly-owned by Elan Corporation, and Idun Pharmaceuticals, subsequently acquired by Pfizer. As Vice President of Research at Athena, his work led to the clinical development of products for multiple sclerosis, Alzheimer's disease, and neuromuscular disorders. While Executive Vice President, Research at Idun, he led R&D teams that pioneered pharmaceutical applications in the field of programmed cell death, or apoptosis. These efforts led to new approaches to the treatment of hepatitis C, inflammation, and cancer. Dr. Fritz holds an A.B. Degree in Biochemical Sciences from Harvard, a M.Sc. Degree in Physiology from University College London, and a Ph.D. in Biophysics from The Rockefeller University.

Marios Fotiadis is a Managing Director at Enterprise Partners in the Life Sciences practice. Mr. Fotiadis joined Enterprise Partners from Advent International where he worked with the Life Sciences Venture team. Prior to Advent International, Marios was CEO of Achillion Pharmaceuticals (Nasdaq: ACHN), a biotechnology company focused on the development of novel treatments for infectious diseases. Before joining Achillion, Marios managed the life sciences venture portfolio of SG Capital Partners, a $550 million private equity fund with more than $80 million invested in biotechnology companies. He joined SG Capital Partners after providing investment banking and M&A advisory services with SG Cowen Securities. Marios has held positions on the boards of directors of several companies, including Achillion Pharmaceuticals, Anadys Pharmaceuticals (Nasdaq: ANDS), Trident Pharmaceuticals, Inc. and Spear Therapeutics, Ltd. Mr. Fotiadis holds an M.B.A. from Columbia University and a B.S.B.A. degree, cum laude in Business Administration, from the Daniels College of Business at the University of Denver.

Mark G. Foletta , CPA, age 48, joined our Board of Directors in September 2005. Mr. Foletta has served as Senior Vice President, Finance and Chief Financial Officer at Amylin Pharmaceuticals Inc., a biopharmaceutical company, since March 2006. He had previously served as Vice President, Finance and Chief Financial Officer at Amylin since March 2000. He served as a Principal of Triton Group Management, Inc., a management consulting firm, from 1997 to 2000. From 1986 to 1997, Mr. Foletta held a number of management positions with Intermark, Inc., a diversified holding company, and Triton Group Ltd., a management consulting firm, the most recent of which was Senior Vice President, Chief Financial Officer and Corporate Secretary. From 1982 to 1986, Mr. Foletta was with Ernst & Young, a public accounting firm, most recently serving as an Audit Manager. Mr. Foletta earned his B.A. in Business Economics from the University of California, Santa Barbara. Mr. Foletta is a certified public accountant.

Steven H. Holtzman , age 55, has served as our Chief Executive Officer and Chair of our board of directors since September 2006, and as our president from October 2007 to October 2008. Mr. Holtzman is also a co-founder of Old Infinity and served as its Chief Executive Officer and as Chair of its board of directors from inception in 2001 through completion of the reverse merger. Mr. Holtzman has also served as President of Old Infinity from July 2001 to February 2006. From 1994 to 2001, Mr. Holtzman served as Chief Business Officer of Millennium Pharmaceuticals, Inc., a publicly-traded pharmaceutical company. From 1996 to 2001, Mr. Holtzman served as a presidential appointee to the National Bioethics Advisory Commission, the principal advisory body to the President and Congress on ethical issues in the biomedical and life sciences. Prior to joining Millennium Pharmaceuticals, Inc., from 1986 to 1994, Mr. Holtzman was a founder and Executive Vice President of DNX Corporation, a publicly-traded biotechnology company. Mr. Holtzman is a director of Anadys Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company, and a trustee of the Berklee College of Music. Mr. Holtzman received a B.A. in Philosophy from Michigan State University and a B.Phil. in Philosophy from Oxford University, which he attended as a Rhodes Scholar.